Advancements in Treating and Managing Long-Chain Fatty Acid Oxidation Disorders, featuring a Patient Perspective

Advancements in Treating and Managing Long-Chain Fatty Acid Oxidation Disorders, featuring a Patient Perspective 

On-Demand 1.5-hour Accredited Webcast

Faculty Presenters

Jerry Vockley, MD, PhD
Cleveland Family Endowed Chair in Pediatric Research
Professor of Human Genetics
University of Pittsburgh

Chief of Genetic and Genomic Medicine
Director of the Center for Rare Disease Therapy
UPMC Children’s Hospital of Pittsburgh
Pittsburgh, Pennsylvania

Richard J. Faris, PhD, MS, RPh
Senior Vice President, Pharmacy
PANTHERx Rare Pharmacy
Pittsburgh, Pennsylvania
 
Program Description
Long-chain fatty acid oxidation disorders (LC-FAODs) are rare, life-threatening, genetic disorders characterized by acute crises of energy production and chronic energy deficiency. These defects in energy production can lead to serious metabolic complications including hypoglycemia and recurrent rhabdomyolysis resulting in frequent hospitalizations and premature death. The management of patients with LC-FAODs is multifactorial and requires comprehensive counseling about appropriate diet and lifestyle precautions often involving the support of a dietician. Until recently, there were no FDA-approved therapies for patients with LC-FAODs. This activity will focus on current treatment options and provide specialty and managed care pharmacists with a better understanding of the management of these rare disorders and their impact on the lives of patients and caregivers through a patient interview.

Target Audience: Managed care and specialty pharmacists
Type of Activity: Application
Release date: May 24, 2021
Expiration date: May 24, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Analyze the pathophysiology and clinical presentation associated with the most common long-chain fatty acid oxidation disorders (LC-FAODs) including significant disease-related complications and impact on patient quality of life
• Explain the limitations of current standards of care for managing LC-FAODs and the role of triheptanoin in treatment including safety and efficacy data
• Explore the role of specialty pharmacists and managed care providers in improving patient access to triheptanoin and their impact in improving patient outcomes 

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-217-H01-P. The activity is available for CE credit through May 24, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Jerry Vockley, MD, PhD, has the following financial relationships with commercial interests to disclose:

• Grant/Research Support: Ultragenyx Pharmaceutical, Reneo Pharmaceuticals, Moderna

Richard J. Faris, PhD, MS, RPh, has the following financial relationship with a commercial interest to disclose:

• Employed by PANTHERx Rare Pharmacy

Patient Perspective Interviewee
Tasia Rechisky has the following disclosure:

• Consultant for the Ultragenyx Patient Leadership Council

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms